Cogent Biosciences plans multiple 2026 drug launches, reports $866M cash and Q1 net loss of $97M

Cogent Biosciences announced plans to launch bezuclastinib for Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) in the second half of 2026, supported by positive Phase 3 trial data. The company ended Q1 2026 with $866.4 million in cash, enough to fund operations through 2028. Research and development expenses rose due to pipeline advancements, while net loss increased to $97.4 million. Upcoming milestones include NDA submissions, clinical trial presentations, and new drug development programs.